Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents

Giuseppe Pizzo, Olga Di Fede, Giuseppina Campisi, Alberto Bedogni, Stefano Fedele, Vittorio Fusco

Risultato della ricerca: Article

49 Citazioni (Scopus)

Abstract

Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonatesand denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-relatedevents in patients with metastatic bone cancer and multiple myeloma. Available data suggestthat 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There isincreasing evidence that avoidance of surgical trauma and infection to the jawbones canminimize the risk of ONJ, but there are still a significant number of individuals who developONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is nodefinitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However,most ONJ individuals are affected by advanced incurable cancer and are often managedwith minimally invasive nonsurgical interventions in order to control jawbone infectionsand painful symptoms. This article summarizes current knowledge of ONJ epidemiology,manifestations, risk-reduction and therapeutic strategies. Further research is needed inorder to determine individual predisposition to ONJ and clarify the effectiveness of availabletreatments.
Lingua originaleEnglish
pagine (da-a)257-275
Numero di pagine19
RivistaFuture Oncology
Volume10
Stato di pubblicazionePublished - 2014

Fingerprint

Bone Density Conservation Agents
Osteonecrosis
Risk Reduction Behavior
Jaw
Epidemiology
Neoplasms
Therapeutics
Bone Neoplasms
Multiple Myeloma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

@article{5d9065d65c8341beaa80ebb4cad3b924,
title = "Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents",
abstract = "Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonatesand denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-relatedevents in patients with metastatic bone cancer and multiple myeloma. Available data suggestthat 0–27.5{\%} of individuals exposed to antiresorptive agents can develop ONJ. There isincreasing evidence that avoidance of surgical trauma and infection to the jawbones canminimize the risk of ONJ, but there are still a significant number of individuals who developONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is nodefinitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However,most ONJ individuals are affected by advanced incurable cancer and are often managedwith minimally invasive nonsurgical interventions in order to control jawbone infectionsand painful symptoms. This article summarizes current knowledge of ONJ epidemiology,manifestations, risk-reduction and therapeutic strategies. Further research is needed inorder to determine individual predisposition to ONJ and clarify the effectiveness of availabletreatments.",
author = "Giuseppe Pizzo and {Di Fede}, Olga and Giuseppina Campisi and Alberto Bedogni and Stefano Fedele and Vittorio Fusco",
year = "2014",
language = "English",
volume = "10",
pages = "257--275",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents

AU - Pizzo, Giuseppe

AU - Di Fede, Olga

AU - Campisi, Giuseppina

AU - Bedogni, Alberto

AU - Fedele, Stefano

AU - Fusco, Vittorio

PY - 2014

Y1 - 2014

N2 - Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonatesand denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-relatedevents in patients with metastatic bone cancer and multiple myeloma. Available data suggestthat 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There isincreasing evidence that avoidance of surgical trauma and infection to the jawbones canminimize the risk of ONJ, but there are still a significant number of individuals who developONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is nodefinitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However,most ONJ individuals are affected by advanced incurable cancer and are often managedwith minimally invasive nonsurgical interventions in order to control jawbone infectionsand painful symptoms. This article summarizes current knowledge of ONJ epidemiology,manifestations, risk-reduction and therapeutic strategies. Further research is needed inorder to determine individual predisposition to ONJ and clarify the effectiveness of availabletreatments.

AB - Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonatesand denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-relatedevents in patients with metastatic bone cancer and multiple myeloma. Available data suggestthat 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There isincreasing evidence that avoidance of surgical trauma and infection to the jawbones canminimize the risk of ONJ, but there are still a significant number of individuals who developONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is nodefinitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However,most ONJ individuals are affected by advanced incurable cancer and are often managedwith minimally invasive nonsurgical interventions in order to control jawbone infectionsand painful symptoms. This article summarizes current knowledge of ONJ epidemiology,manifestations, risk-reduction and therapeutic strategies. Further research is needed inorder to determine individual predisposition to ONJ and clarify the effectiveness of availabletreatments.

UR - http://hdl.handle.net/10447/87083

M3 - Article

VL - 10

SP - 257

EP - 275

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -